Video

Patient Profile 2: A 62-Year-Old Woman with Metastatic HR+ Breast Cancer

Author(s):

Massimo Cristofanilli, MD, FACP,Sara M. Tolaney, MD, MPH

Massimo Cristofanilli, MD, and Sara Tolaney, MD, MPH, analyze a patient case of a 62-year-old woman with metastatic HR+ breast cancer.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™
Video

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

May 9th 2025 - Jun 14th 2025

online-activity
View More
Proactive Adverse Event Management for HER2+ BTC Treatments
Video

Proactive Adverse Event Management for HER2+ BTC Treatments

May 8th 2025 - May 9th 2026

online-activity
View More
Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina
Video

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

May 2nd 2025 - Jun 7th 2025

online-activity
View More
Related Content
Leptomeningeal Metastases | Image Credit: © Joshua – stock.adobe.com
May 14th 2025

Rhenium (Re186) Obisbemeda Shows Initial Safety, Clinical Benefit in Leptomeningeal Metastases

MedNews Week
January 1st 2025

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

The Inflation Reduction Act Affects Oncology | Image credit: © Valeri Luzina – stock.adobe.com
May 9th 2025

Inflation Reduction Act Leads to Seesaw Effect Between Oncologic Drug Savings and Development

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Arielle Heeke, MD
Published: May 2nd 2025 | Updated: May 6th 2025

Adjuvant CDK4/6 Inhibition Gains Further Ground in HR+/HER2– Early Breast Cancer With Ribociclib Approval

Invasive Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
May 2nd 2025

5-Year Phase 2 Data Show 0% Recurrence Rate After Surgery Omission in Select Patients With Invasive Breast Cancer